Berberine and Fatty Liver

What the trials measured

Non-alcoholic fatty liver disease (NAFLD) is characterized by excess fat in the liver and is commonly tracked using blood markers of liver function. A 2024 meta-analysis that pooled 10 randomized controlled trials, covering 811 patients, examined whether berberine taken as an adjunct affected these markers. The primary outcomes included liver enzymes such as alanine transaminase (ALT), aspartate transaminase (AST) and glutamyl transpeptidase (GGT), as well as lipid indices, insulin resistance and body mass index.^[1]

In that pooled analysis, berberine was associated with statistically significant reductions in the liver enzymes ALT, AST and GGT compared with control. The authors framed berberine as a potential adjunct therapy rather than a stand-alone treatment, and the size of the effect varied across the included trials.^[1]

Tolerability reported in the trials

Across the randomized controlled trials gathered in the 2024 meta-analysis, the authors reported a favorable safety profile for berberine, noting only mild gastrointestinal adverse events among participants. This reflects short-to-medium-term tolerability within the studied trials and does not establish long-term safety.^[1]

How strong is the evidence

The supporting evidence remains limited in scope. The 2024 meta-analysis drew on 10 generally small trials, and a 2025 systematic review and meta-analysis was able to pool only four clinical trials alongside 18 preclinical animal studies. Both reviews note that berberine doses were not standardized across studies and explicitly call for further rigorous, well-designed trials before firm conclusions can be drawn.^{[1], [2]}

Taken together, the current human evidence points toward improvements in liver enzymes and a generally mild adverse-event profile, but the modest number of trials, non-standardized dosing and reliance on biochemical markers mean these findings are best read as promising rather than definitive. This article is informational and is not medical advice.^{[1], [2]}

Limitations

Findings come from meta-analyses of a small number of mostly small randomized controlled trials with non-standardized berberine doses, varying durations and significant heterogeneity in some outcomes, and the 2025 review combined limited clinical data with preclinical animal studies. Outcomes were biochemical markers such as liver enzymes rather than long-term clinical endpoints, so the durability and real-world relevance of these effects remain uncertain.^{[1], [2]}